Executive Summary

Oct 2019
PROSPECTS
Competition from non-OTC dermatologicals and limited product variety restricts growth

Despite the rise of self-medication in Greece, its impact is not being fully felt in dermatologicals, as there is a limited range of OTC products available. The majority of sales of products to treat skin conditions derive from non-OTC brands, with these often being sold under the counter.

High prices and a lack of demand likely to deter investment

Consumers remain price sensitive in post-recession Greece, especially when treating minor conditions. Although a number of lines of added value dermatologicals were launched towards the end of the review period their appeal is limited.

Herbal/traditional dermatologicals benefit from natural image

While standard dermatologicals saw only steady growth in current value terms in 2019, herbal/traditional dermatologicals saw dynamic growth. This is down to the growing interest among younger generations in using natural alternatives to standard medicines where possible.

COMPETITIVE LANDSCAPE
Johnson & Johnson benefiting from large portfolio of products

With a wide product portfolio and strong brands, such as Daktarin, Regaine and Fungoral, Johnson & Johnson Hellas SA is the leading player in dermatologicals. Regaine dominates hair loss treatments with its value share continuing to grow in 2019 with it now offering products for both men and women following the launch of Regaine Women’s foam earlier in the review period.

Threat from herbal/traditional products presents challenge to Fenistil

Similarly, GSK Consumer Healthcare also offers a large portfolio of dermatologicals, with it adding Pfizer’s Preparation H brand, which leads haemorrhoid treatments, to its range following the decision to combine the two companies’ portfolios. The company’s Fenistil brand dominates topical allergy remedies/antihistamines and is the second biggest brand in dermatologicals overall.

Betadine remains king in topical germicidals/antiseptics but Oxisept benefits from low pricing

Lavipharm SA retained third place in the rankings in 2019 with it benefiting from the popularity of its Betadine brand, which is accounts for most sales of topical germicidals/antiseptics in Greece. Its low retail price coupled with strong consumer awareness have helped the brand to maintain its dominance, while it also faces little competition.

Want to find out more about this report?
Request more information
Why buy this report?

Gain competitive intelligence about market leaders. Track key industry trends, opportunities and threats. Inform your marketing, brand, strategy and market development, sales and supply functions.

Your Recently Viewed Reports

Dermatologicals in Greece

Samples (FAQs about samples):

Delivery: Files are delivered directly into your account within a few minutes of purchase.

Overview

Discover the latest market trends and uncover sources of future market growth for the Medicated Skin Care industry in Greece with research from Euromonitor's team of in-country analysts.

Find hidden opportunities in the most current research data available, understand competitive threats with our detailed market analysis, and plan your corporate strategy with our expert qualitative analysis and growth projections.

If you're in the Medicated Skin Care industry in Greece, our research will save you time and money while empowering you to make informed, profitable decisions.

The Medicated Skin Care in Greece market research report includes:

  • Analysis of key supply-side and demand trends
  • Detailed segmentation of international and local products
  • Historic volumes and values, company and brand market shares
  • Five year forecasts of market trends and market growth
  • Robust and transparent market research methodology, conducted in-country

Our market research reports answer questions such as:

  • What is the market size of Medicated Skin Care in Greece?
  • What are the major brands in Greece?
  • What are the most popular formats for acne treatments?

Why buy this report?

  • Gain competitive intelligence about market leaders
  • Track key industry trends, opportunities and threats
  • Inform your marketing, brand, strategy and market development, sales and supply functions

This industry report originates from Passport, our Consumer Health market research database.

Dermatologicals in Greece - Category analysis

HEADLINES

PROSPECTS

Competition from non-OTC dermatologicals and limited product variety restricts growth
High prices and a lack of demand likely to deter investment
Herbal/traditional dermatologicals benefit from natural image

COMPETITIVE LANDSCAPE

Johnson & Johnson benefiting from large portfolio of products
Threat from herbal/traditional products presents challenge to Fenistil
Betadine remains king in topical germicidals/antiseptics but Oxisept benefits from low pricing

CATEGORY DATA

Table 1 Sales of Dermatologicals by Category: Value 2014-2019
Table 2 Sales of Dermatologicals by Category: % Value Growth 2014-2019
Table 3 NBO Company Shares of Dermatologicals: % Value 2015-2019
Table 4 LBN Brand Shares of Dermatologicals: % Value 2016-2019
Table 5 Forecast Sales of Dermatologicals by Category: Value 2019-2024
Table 6 Forecast Sales of Dermatologicals by Category: % Value Growth 2019-2024

Consumer Health in Greece - Industry Overview

EXECUTIVE SUMMARY

Growth becomes more stable following liberation of prices and distribution
Consumers paying more attention to their health
New players make strong entry while GSK and Vian compete for the lead
Internet retailing flourishing despite limited presence in OTC
Future appears bright for consumer health in Greece thanks to changing attitudes

MARKET INDICATORS

Table 7 Consumer Expenditure on Health Goods and Medical Services: Value 2014-2019
Table 8 Life Expectancy at Birth 2014-2019

MARKET DATA

Table 9 Sales of Consumer Health by Category: Value 2014-2019
Table 10 Sales of Consumer Health by Category: % Value Growth 2014-2019
Table 11 NBO Company Shares of Consumer Health: % Value 2015-2019
Table 12 LBN Brand Shares of Consumer Health: % Value 2016-2019
Table 13 Distribution of Consumer Health by Format: % Value 2014-2019
Table 14 Distribution of Consumer Health by Format and Category: % Value 2019
Table 15 Forecast Sales of Consumer Health by Category: Value 2019-2024
Table 16 Forecast Sales of Consumer Health by Category: % Value Growth 2019-2024

APPENDIX

OTC registration and classification
Vitamins and dietary supplements registration and classification
Self-medication/self-care and preventive medicine
Switches

DEFINITIONS

SOURCES

Summary 1 Research Sources